Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Debut: DePuy Synthes Solidifies Knee Biz With Attune Revision's EMEA Launch

Executive Summary

J&J/DePuy Synthes launched the Attune Revision Knee System to complement its Attune Primary Knee System in Europe, Middle East, and Africa. The launch was formally announced at the European Federation of the National Associations of Orthopedics and Traumatology (EFORT) Congress in Barcelona.

You may also be interested in...



Earnings Winners & Losers: Orthopedics Firms, JNJ, NUVA, SNN, SYK, ZBH

With earnings reporting season now in full swing, Medtech Insight highlights which companies have exceeded expectations and which ones continue to see their bottom-line sink. This edition throws the spotlight on some of the notable players in the orthopedics space.

Minute Insight: Apple Watch Helps Knee-Replacement Patients In Zimmer Biomet-Sponsored Trial

One-year data from a randomized controlled trial showed Zimmer Biomet’s mymobility app paired with the Apple Watch can effectively guide rehabilitation following knee-replacement surgery.

Speculation On Baxter Division Picks Up Steam

The company reported in October that it was reviewing its portfolio and would offer more details on its future plans in January. Wells Fargo analysts expect Baxter to split its fast-growing connected care business from its lower-margin hospital-based therapeutics products.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT122748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel